γ Irradiated Mycobacteria Enhance Survival in Bladder Tumor Bearing Mice Although Less Efficaciously than Live Mycobacteria
- PMID: 26165584
- DOI: 10.1016/j.juro.2015.07.011
γ Irradiated Mycobacteria Enhance Survival in Bladder Tumor Bearing Mice Although Less Efficaciously than Live Mycobacteria
Abstract
Purpose: γ Irradiated Mycobacterium bovis bacillus Calmette-Guérin has shown in vitro and ex vivo antitumor activity. However, to our knowledge the potential antitumor capacity has not been demonstrated in vivo. We studied the in vivo potential of γ irradiated bacillus Calmette-Guérin and γ irradiated M. brumae, a saprophytic mycobacterium that was recently described as an immunotherapeutic agent.
Materials and methods: The antitumor capacity of γ irradiated M. brumae was first investigated by analyzing the in vitro inhibition of bladder tumor cell proliferation and the ex vivo cytotoxic effect of M. brumae activated peripheral blood cells. The effect of γ irradiated M. brumae or bacillus Calmette-Guérin intravesical treatment was then compared to treatment with live mycobacteria in the orthotopic murine model of bladder cancer.
Results: Nonviable M. brumae showed a capacity to inhibit in vitro bladder cancer cell lines similar to that of live mycobacteria. However, its capacity to induce cytokine production was decreased compared to that of live M. brumae. γ Irradiated M. brumae could activate immune cells to inhibit tumor cell growth, although to a lesser extent than live mycobacteria. Finally, intravesical treatment with γ irradiated M. brumae or bacillus Calmette-Guérin significantly increased survival with respect to that of nontreated tumor bearing mice. Both γ irradiated mycobacteria showed lower survival rates than those of live mycobacteria but the minor efficacy of γ irradiated vs live mycobacteria was only significant for bacillus Calmette-Guérin.
Conclusions: Our results show that although γ irradiated mycobacteria is less efficacious than live mycobacteria, it induces an antitumor effect in vivo, avoiding the possibility of further mycobacterial infections.
Keywords: BCG vaccine; Mycobacterium; gamma rays; immunotherapy; urinary bladder neoplasms.
Copyright © 2016 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Comment in
-
Getting the Most Out of bacillus Calmette-Guérin for Treatment of Bladder Cancer.J Urol. 2016 Jan;195(1):7-8. doi: 10.1016/j.juro.2015.10.024. Epub 2015 Oct 9. J Urol. 2016. PMID: 26456281 No abstract available.
Similar articles
-
Killed but metabolically active Mycobacterium bovis bacillus Calmette-Guérin retains the antitumor ability of live bacillus Calmette-Guérin.J Urol. 2014 May;191(5):1422-8. doi: 10.1016/j.juro.2013.12.002. Epub 2013 Dec 10. J Urol. 2014. PMID: 24333111
-
Nonpathogenic Mycobacterium brumae Inhibits Bladder Cancer Growth In Vitro, Ex Vivo, and In Vivo.Eur Urol Focus. 2016 Apr;2(1):67-76. doi: 10.1016/j.euf.2015.03.003. Epub 2015 Jun 6. Eur Urol Focus. 2016. PMID: 28723453
-
Getting the Most Out of bacillus Calmette-Guérin for Treatment of Bladder Cancer.J Urol. 2016 Jan;195(1):7-8. doi: 10.1016/j.juro.2015.10.024. Epub 2015 Oct 9. J Urol. 2016. PMID: 26456281 No abstract available.
-
Bacillus Calmette-Guerin (BCG): Its fight against pathogens and cancer.Urol Oncol. 2021 Feb;39(2):121-129. doi: 10.1016/j.urolonc.2020.09.031. Epub 2020 Nov 28. Urol Oncol. 2021. PMID: 33262028 Review.
-
Should intravesical Bacillus Calmette-Guérin be employed in transplant recipients with bladder carcinoma?Transpl Infect Dis. 2010 Aug 1;12(4):358-62. doi: 10.1111/j.1399-3062.2010.00506.x. Epub 2010 Apr 19. Transpl Infect Dis. 2010. PMID: 20412534 Review.
Cited by
-
Genomic analysis of Mycobacterium brumae sustains its nonpathogenic and immunogenic phenotype.Front Microbiol. 2023 Jan 5;13:982679. doi: 10.3389/fmicb.2022.982679. eCollection 2022. Front Microbiol. 2023. PMID: 36687580 Free PMC article.
-
Remodeling the bladder tumor immune microenvironment by mycobacterial species with changes in their cell envelope composition.Front Immunol. 2022 Oct 11;13:993401. doi: 10.3389/fimmu.2022.993401. eCollection 2022. Front Immunol. 2022. PMID: 36304456 Free PMC article.
-
Mycobacteria-Based Vaccines as Immunotherapy for Non-urological Cancers.Cancers (Basel). 2020 Jul 5;12(7):1802. doi: 10.3390/cancers12071802. Cancers (Basel). 2020. PMID: 32635668 Free PMC article. Review.
-
Mycolicibacterium brumae Is a Safe and Non-Toxic Immunomodulatory Agent for Cancer Treatment.Vaccines (Basel). 2020 Apr 25;8(2):198. doi: 10.3390/vaccines8020198. Vaccines (Basel). 2020. PMID: 32344808 Free PMC article.
-
Immunotherapy of Bacillus Calmette‑Guérin by targeting macrophages against bladder cancer in a NOD/scid IL2Rg‑/‑ mouse model.Mol Med Rep. 2020 Jul;22(1):362-370. doi: 10.3892/mmr.2020.11090. Epub 2020 Apr 22. Mol Med Rep. 2020. PMID: 32319653 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
